Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients
Abstract Neuroendocrine prostate cancer (NEPC), a highly aggressive variant of castration-resistant prostate cancer (CRPC), often emerges upon treatment with androgen pathway inhibitors, via neuroendocrine differentiation. Currently, NEPC diagnosis is challenging as available markers are not suffici...
Guardado en:
Autores principales: | Divya Bhagirath, Michael Liston, Theresa Akoto, Byron Lui, Barbara A. Bensing, Ashok Sharma, Sharanjot Saini |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d5214699fc2a4b7883f1e1dd59762ab6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance
por: Wei-Yu Chen, et al.
Publicado: (2021) -
Imaging of Neuroendocrine Prostatic Carcinoma
por: Ahmed Taher, et al.
Publicado: (2021) -
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Shangwei Zhong, et al.
Publicado: (2021) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Castration-resistant prostate cancer: potential targets and therapies
por: Parray A, et al.
Publicado: (2012)